

COVID-19 Vaccination

Fauzia Khan, Director Immunization Service



STATEWIDE COVID-19 VACCINE DOSES DELIVERED (AS OF 5/5/2021)

Across Oklahoma,
2,600,915
COVID-19 vaccine
doses have been
delivered



1,313,715 COVID-19
vaccine doses



1,155,700 COVID-19
vaccine doses



131,500 COVID-19
vaccine doses

STATEWIDE COVID-19 VACCINE ADMINISTRATION (AS OF 5/4/2021)

1,308,444
people have
received **at least 1**
dose* of the
COVID-19 vaccine



1,044,583
people are **fully**
vaccinated** with
the COVID-19
vaccine



Across Oklahoma, a total of **2,283,725**
COVID-19 vaccine doses have been **administered**
since 12/14/2020

*Refers to individuals receiving Pfizer and Moderna COVID-19 vaccines and/or receiving single shot of J&J/Janssen Vaccine

**Refers to individuals fully vaccinated after receiving either Pfizer and/or Moderna COVID-19 vaccines (both doses) and/or receiving single shot of J&J/Janssen Vaccine

Note: Total vaccines administered does not include doses administered by federal entities (Bureau of Prisons, Veterans Health, Indian Health Service, or Department of Defense).


Not for public distribution, data intended for internal planning purposes.

Data Source: COVID-19 Vaccination Reporting Specification (CVRS) Dataset - Oklahoma State Immunization Information System (OSIIS); Data reflect information entered as of 11:59PM 5/4/2021



STATE COVID-19 VACCINE ADMINISTRATION BREAKDOWN - FULLY VACCINATED (AS OF 5/4/2021)


Among the **1,044,583 people** who are **fully vaccinated**, the **majority** are **female**




Among the **1,044,583 people** who are **fully vaccinated**, the **ages** range between **16-109 years**



Primary Race



Ethnicity



Note: Fully vaccinated refers to individuals completing series after receiving either Pfizer and/or Moderna COVID-19 vaccines (both doses) and/or receiving single shot of J&J/Janssen Vaccine.

Not for public distribution, data intended for internal planning purposes.

Data Source: COVID-19 Vaccination Reporting Specification (CVRS) Dataset - Oklahoma State Immunization Information System (OSIIS); Data reflect information entered as of 11:59PM 5/4/2021

STATE COVID-19 VACCINE ADMINISTRATION BREAKDOWN - FULLY VACCINATED (AS OF 5/4/2021)

Demographic Summary	Total Population >16 years of age	People who are Fully Vaccinated	Percent who are Fully Vaccinated
Oklahoma	3,110,214	1,044,583	33.6%
Gender			
Male	1,528,522 (49.1%)	464,900	30.4%
Female	1,582,692 (50.9%)	578,169	36.5%
Unknown	-	1,514	
Age Group			
16-17	105,481 (3.4%)	9,055	8.6%
18-35	976,999 (31.4%)	184,059	18.8%
36-49	675,766 (21.7%)	191,929	28.4%
50-64	716,836 (23%)	279,803	39.0%
65+	635,132 (20.4%)	379,721	59.8%
Race			
White	2,366,465 (76.1%)	709,719	30.0%
Black	236,099 (7.6%)	45,533	19.3%
Asian/PI	82,291 (2.6%)	32,350	39.3%
American Indian	281,001 (8.7%)	46,269	17.1%
Other	154,358 (5%)	26,550	17.2%
Unknown	-	184,162	
Ethnicity			
Hispanic	286,504 (9.2%)	66,958	23.4%
Not Hispanic	2,823,710 (90.8%)	728,383	25.8%
Unknown	-	249,242	

Note: : Fully vaccinated refers to individuals completing series after receiving either Pfizer and/or Moderna COVID-19 vaccines (both doses) and/or receiving single shot of J&J/Janssen Vaccine.

Data Source: 1. Single-race Population Estimates, United States, 2010-2019. July 1st resident population by state, age, sex, single-race, and Hispanic origin, on CDC WONDER Online Database. Vintage 2019 estimates released by U.S. Census Bureau on June 25, 2020 COVID-19 2. Vaccination Reporting Specification (CVRS) Dataset- Oklahoma State Immunization Information System (OSIIS); Data reflect information entered as of 11:59PM 5/4/2021



Location	Age group	Data Type	2019
Oklahoma	12 to 14	Number	161,833
		Percent	17%
	15 to 17	Number	158,657
		Percent	17%

Estimated Total Eligible Population = 3,324,933 (84% of total population)



Data Source: Annie E. Casey Foundation, Kids Count Data Center, Child Population by age group in Oklahoma, as of September 2020.

- May 4: Pfizer submits EUA request for its 12-15 age range pediatric vaccine
 - Prior SARS-CoV-2 infection was not taken into account
 - Vaccine used: mRNA BNT162b2 formulation
- Phase 3 Clinical Trial Data
 - N = 2,260
 - Placebo Group: N = 1,129
 - 18 cases developed SARS-CoV-2 infection
 - Vaccinated Group: N = 1,131
 - 0 cases developed SARS-CoV-2 infection
 - Vaccines and Related Biological Products Advisory Committee (VRBPAC) waived meeting citing that the safety information was still relevant
 - Good Clinical Practice (GCP) safety measures are required at every clinical trial
- Results:
 - Pfizer/BioNTech showed 100% efficacy and robust antibody responses
 - exceeding response reported in trials of 16-25 year old participants
 - Side Effects reported same as those experienced by 16-25 age range receiving Pfizer



- Pfizer/BioNTech Pediatric:
 - Seeking EUA for 2-11 years in September
 - Definitive Results of Phase 3 trials will be ready for submission
 - 6 months to 2 years results expected Q4 of 2021

- Moderna Pediatric:
 - Testing in children from 6 months to 17 years
 - Plan to ask FDA for EUA later this year
 - No definite date

